EGFR and neoplasm: Collectively, these data warrant investigation into the roles of EGFR in different subtypes of HNSCC to help stratifying patients who are likely to benefit from EGFR-targeted therapy, particularly in HPV-positive tumours, in which inhibition of EGFR could potentially worsen therapy response.